HIMS
Hims & Hers
Market cap$6.22B
Updated - ago
Hims & Hers shares moved down 1.12% to $25.987 as investors weighed a newly announced partnership with Eli Lilly to offer obesity medications against caution ahead of upcoming third-quarter financial results.1 Market participants balanced the expanded weight-loss portfolio with pre-earnings positioning and potential margin pressures.1
Hims & Hers Health, Inc. is a telehealth company that provides direct-to-consumer healthcare services and prescription medications through an integrated digital platform. Founded in 2018, the company operates by connecting patients with licensed healthcare providers via online consultations, enabling users to receive diagnoses, treatment plans, and medications delivered to their homes. Hims & Hers offers a broad range of services including treatments for conditions such as erectile dysfunction, hair loss, acne, weight management, and mental health issues, along with preventive care and chronic disease management. The company generates revenue primarily through consultation fees and by dispensing prescription medications through its licensed pharmacy operations. As a publicly traded company on the New York Stock Exchange under the ticker symbol HIMS, it represents a significant player in the digital healthcare space, disrupting traditional healthcare delivery models by reducing barriers to access and lowering costs for consumers seeking convenient medical services.